Ocaratuzumab

Tax included
Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC).
MedChemExpress 
HY-P99308

Data sheet

Size
Multiple sizes
Reactivity
CD20
Application
Cancer-programmed cell death
CAS
1169956-08-4